{"id":"venetoclax-decitabine-azacitidine-association","safety":{"commonSideEffects":[{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Venetoclax's mechanism of action involves binding to BCL-2, preventing its anti-apoptotic function, thereby allowing for programmed cell death. Decitabine and Azacitidine, on the other hand, act as hypomethylating agents, which means they reduce DNA methylation, leading to the reactivation of silenced genes and the induction of apoptosis in cancer cells.","oneSentence":"Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine work as hypomethylating agents to restore normal gene expression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:29.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"}]},"trialDetails":[{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT06972641","phase":"PHASE2, PHASE3","title":"Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-06-10","conditions":"AML, MDS","enrollment":126},{"nctId":"NCT04476199","phase":"PHASE2","title":"Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Trapianto di Midollo Osseo","startDate":"2019-12-09","conditions":"Acute Myeloid Leukemia","enrollment":100},{"nctId":"NCT05264883","phase":"PHASE3","title":"Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-03-01","conditions":"Acute Myeloid Leukemia","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Venetoclax-Decitabine/Azacitidine Association","genericName":"Venetoclax-Decitabine/Azacitidine Association","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Venetoclax targets and inhibits BCL-2, a protein that prevents apoptosis, while Decitabine/Azacitidine work as hypomethylating agents to restore normal gene expression. Used for Acute myeloid leukemia (AML).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}